166P Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients

The clinical benefits of immunotherapy are limited for unselected EGFR+ lung adenocarcinoma (LUAD). Conventional biomarkers like PD-L1 or TMB are not sufficient for these patients. Additionally, efficacy of EGFR-TKIs among EGFR+/TP53+ patients are significantly inferior to EGFR+/TP53- patients and subsequent treatment strategy are even more important. We conducted an integrated analysis to investigate the influence of TP53 mutation in immunotherapy efficacy and tumor microenvironment (TME) among EGFR+ LUAD.